# KTTA — Pasithea Therapeutics Corp · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** KTTA  
**Sources:** 18  
**Published:** 2026-10-31  
**Canonical:** https://app.k3vl4r.com/research/deep-research-ktta-pasithea-therapeutics-corp-catalysts-narrative-risk-10417

---

# Pasithea Therapeutics Corp. (NASDAQ: KTTA) — Point-in-Time Research Snapshot (as of 2026-10-31)

**Company basics:** Pasithea is a clinical-stage biotech on the NASDAQ Capital Market developing PAS-004, a next-generation macrocyclic oral MEK inhibitor targeting RASopathies (including NF1), MAPK pathway-driven tumors, and other diseases (CNS disorders, ETS2-driven diseases like ID) [[2]](https://finance.yahoo.com/healthcare/articles/pasithea-therapeutics-announces-positive-pas-131500493.html), [[7]](https://ir.pasithea.com/), [[18]](https://stockanalysis.com/stocks/ktta/). As of 2026-10-31, it is a micro-capitalization company (~$12.37M market cap), pre-revenue, with a stock price around $0.37 and net losses of roughly -$20 to -$21M over the trailing year [[18]](https://stockanalysis.com/stocks/ktta/), [[19]](https://www.cnn.com/markets/stocks/KTTA).

---

## Key Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-ktta-pasithea-therapeutics-corp-catalysts-narrative-risk-10417 (free to sign up)._